Trovagene and Strand Life Sciences Collaborate on Urine-Based HPV Screening Test

Trovagene, Inc. (San Diego, CA, USA), a developer of transrenal molecular diagnostics, and Strand Life Sciences Pvt Ltd. (Bangalore, India), which offers predictive systems modeling, data integration, and context management for research and laboratory professionals, announced they are collaborating on a urine-based Human Papillomavirus (HPV) test.

The companies entered into a Memorandum of Understanding (MOU) to license and validate Trovagene's proprietary Human Papillomavirus (HPV) urine test and High Risk HPV DNA Assay for clinical diagnostic and screening use in India and countries in the South Asian Association for Regional Cooperation (SAARC).

The companies will assess the accuracy of urine as a specimen for diagnostic purposes, as well as for determining stages of disease progression. If successful, the urine test will serve as a non-invasive alternative to standard cytology and PAP staining tests for the detection of HPV.

"The potential to use urine, an easily obtained and stable testing sample, for high risk HPV carrier screening across medically underserved areas is very promising," said Vijay Chandru, PhD, chairman and chief executive officer, Strand Life Sciences. "We are pleased to be working with Trovagene, a leader in this field, on this important project that has the potential to make HPV screening broadly available in the region and to become a new standard of care."

Strand Life Sciences also intends to explore and validate the clinical use of HPV DNA testing as a risk indicator and pathological cause of oral cancer in buccal swabs, biopsies, and saliva/sputum specimens.



Related Links:


Trovagene, Inc.
Strand Life Sciences Pvt Ltd.